Efficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial.

Toong-Hua Liang Chyou-Shen Lee Shinn-Shing Lee Chien-Sheng Wu Kun-Hung Chen Ping-Ning Hsu Hsiao-Yi Lin

Published in: Archives of rheumatology (2020)

Opinercept concurrent with DMARDs was superior to DMARDs alone in slowing RA progression and ameliorating symptoms, with well- tolerated and acceptable safety profile.

Keyphrases

rheumatoid arthritis
rheumatoid arthritis patients
disease activity
ankylosing spondylitis
interstitial lung disease
locally advanced
systemic lupus erythematosus
sleep quality
adverse drug
radiation therapy
depressive symptoms
rectal cancer